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An imbalance between excitatory (E) glutamate and inhibitory (I) GABA transmission may
underlie neurodevelopmental conditions such as autism spectrum disorder (ASD) and
schizophrenia. This may be direct, through alterations in synaptic genes, but there is
increasing evidence for the importance of indirect modulation of E/I balance through
glial mechanisms. Here, we used C57BL/6J mice to test the hypothesis that striatal
glutamate levels can be shifted by N-acetylcysteine (NAC), which acts at the cystine-
glutamate antiporter of glial cells. Striatal glutamate was quantified in vivo using proton
magnetic resonance spectroscopy. The effect of NAC on behaviors relevant to ASD
was examined in a separate cohort. NAC induced a time-dependent decrease in striatal
glutamate, which recapitulated findings of lower striatal glutamate reported in ASD. NAC-
treated animals were significantly less active and more anxious in the open field test; and
NAC-treated females had significantly impaired prepulse inhibition of startle response.
This at least partly mimics greater anxiety and impaired sensorimotor gating reported in
neurodevelopmental disorders. Thus glial mechanisms regulate glutamate acutely and
have functional consequences even in adulthood. Glial cells may be a potential drug
target for the development of new therapies for neurodevelopmental disorders across
the life-span.
Keywords: N-acetylcysteine, magnetic resonance spectroscopy, glutamate, neurodevelopmental disorders,
anxiety, prepulse inhibition
INTRODUCTION
Neurodevelopmental disorders such as autism spectrum disorder (ASD) and schizophrenia
affect about 1% of the population (Saha et al., 2005; Baron-Cohen et al., 2009). Their etiology
is poorly understood, and treatments are limited. However, recent advances in research suggest
an imbalance between excitatory (E) glutamate and inhibitory (I) GABA is a key pathophysiological
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feature that may explain both core and common comorbid
symptoms such as anxiety (Rubenstein and Merzenich, 2003;
Cortese and Phan, 2005; Lewis and Kim, 2009; Coghlan et al.,
2012; Moghaddam and Javitt, 2012).
E/I imbalance in neurodevelopmental conditions can arise
directly via alteration in genes encoding glutamatergic receptors
or synaptic adhesion proteins (Silverman et al., 2012, 2015;
Spooren et al., 2012). For example, the synapse organizers
Neurexins and their binding partner Neuroligins are crucial
to the formation and maintenance of excitatory and inhibitory
synapses. Abnormalities in the genes encoding these proteins
have been reported in both ASD and schizophrenia (Bang
and Owczarek, 2013), and animal models have confirmed
their role in synaptic transmission and behaviors relevant to
neurodevelopmental disorders (Graf et al., 2004; Dahlhaus and
El-Husseini, 2010; Grayton et al., 2013).
However, synaptic gene abnormalities account for only a
relatively small proportion of the neurodevelopmental spectrum
(Devlin and Scherer, 2012); and there is increasing evidence
that E/I balance can also be modulated by glial mechanisms
(Di Benedetto and Rupprecht, 2013). The brain’s glial support
system includes astrocytes, which support and protect neurons;
and microglia, the resident macrophages of the central nervous
system. These cells are now appreciated to have a critical
role in synapse development, maintenance and remodelling
(Koyama and Ikegama), but can also influence excitatory and
inhibitory synaptic transmission (Auld and Robitaille, 2003).
For instance, astrocytes regulate brain levels of glutamate and
GABA through the glutamate/glutamine cycle (Liang et al.,
2006); and activated microglia release glutamate (Domercq
et al., 2013). A role for glial cells in neurodevelopmental
disorders is supported by reports of abnormalities in astrocyte
gene expression in both ASD and schizophrenia (Fatemi
et al., 2008; Bernstein et al., 2009); and an increased number
of activated microglia in adults with ASD (Onore et al.,
2012).
System xc−, the cysteine-glutamate antiporter found on
the cell membrane of glia, is central to their influence on
synaptic transmission. It can be stimulated by the compound
N-Acetylcysteine (NAC, an FDA approved drug) to increase
glutamate in the extrasynaptic space, thereby activating
presynaptic mGluR2/3, which in turn inhibit the synaptic
release of glutamate (Baker et al., 2003; Moran et al., 2005;
Dean et al., 2011; Kupchik et al., 2012). Therefore, in this
study we administered NAC to standard ‘‘wild-type’’ laboratory
C57BL/6J mice to provide proof-of-concept evidence that acute
modulation of glia alters glutamate levels in vivo; and has
functional (behavioral) consequences. We used proton magnetic
resonance spectroscopy (1H-MRS) to quantify glutamate in the
left striatum, as both structural and functional abnormalities
in this area are well documented in neurodevelopmental
disorders (Haznedar et al., 2006; Scott-Van Zeeland et al.,
2010; Simpson et al., 2010; De La Fuente-Sandoval et al., 2011;
Baez-Mendoza and Schultz, 2013; Naaijen et al., 2015). In
a separate cohort we assessed prepulse inhibition of startle
response (PPI), a measure of sensorimotor gating which
is impaired in ASD and schizophrenia (Braff et al., 2001;
McAlonan et al., 2002; Kumari et al., 2003; Perry et al., 2007).
We also measured anxiety in the open field arena, as this
is a common comorbidity of neurodevelopmental disorders
(Braga et al., 2013; Joshi et al., 2013; Matson and Cervantes,
2014).
MATERIALS AND METHODS
Animals
Two cohorts of C57BL/6J mice (Charles River, Margate, Kent,
UK) aged 7–8 weeks were used in the study. Animals were
acclimatized to our facilities for a week before beginning
the experimental procedures, during which they were group
housed (2–4 per cage) in Tecniplast cages (32 cm × 16
cm × 14 cm) with sawdust (Litaspen premium, Datesand
Ltd, Manchester), a cardboard shelter and additional bedding
material (Sizzlenest, Datesand Ltd, Manchester) and maintained
on a 12h/12 h light/dark cycle (07:00–19:00 h) at constant
room temperature (21◦C) and humidity (45%). The mice were
fed a standard diet (Rat and Mouse #1 Diet, Special Diet
Services, Essex, UK) and provided with water ad libitum. Both
sexes were used in this study to avoid sex specific confounds.
The oestrous phase of the female mice was not checked in
this study. However, it is unlikely that this affected results
because there were no major effects in the variance between
males and females. All housing and experimental procedures
were performed in compliance with the local ethical review
panel of King’s College London, and the UK Home Office
Animals Scientific Procedures Act 1986. The work was carried
out under license (PPL: 70/7184) and all efforts were made to
minimize animal suffering and to reduce the number of animals
used.
Drug Treatment
NAC was purchased from Sigma-Aldrich (UK), and dissolved in
saline. Prior to experimental procedures, mice were injected (i.p.)
with either 150 mg/kg NAC solution (30 g/L); injection volume
approximately 100 microL or vehicle (saline).
Proton Magnetic Resonance Spectroscopy
of the Brain
In cohort I, 32 animals (16/sex) were treated with either
NAC or vehicle, 115–175 min before data acquisition began.
Animals were anaesthetized throughout the scan using an
isofluorane/oxygen mix (5% induction, 2% maintenance). Body
temperature and respiratory frequency were monitored and
carefully regulated throughout the procedure.
Data were acquired on a 7T horizontal bore scanner (Agilent
Technologies Inc., Walnut Creek, CA, USA) using a 33 mm
internal diameter quadrature volume coil (Rapid Biomedical,
Rimpar, Germany). The field was shimmed to <14 MHz, width
at half height of the water peak. Pilot MR images for voxel
positioning were acquired using a fast spin-echo sequence with
repetition time(TR) = 1000 ms, effective echo time(TE) = 60 ms,
field of view 20 × 20 mm, 27 contiguous axial slices of 0.5 mm
thickness, and two averages. These MR images were used for
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placement of a voxel (2.2 × 1.3 × 1.9 mm) in the left striatum
for localized 1H-MRS as shown in Figure 1A. Point-RESolved
Spectroscopy (PRESS; Bottomley, 1987) was used to acquire
1H-MRS data from the voxel with acquisition parameters:
TR, 3000 ms; TE, 24 ms; 2048 data points; spectral width,
5208 Hz and 1000 averages. Water suppression was achieved
using VAriable Pulse Power and Optimized Relaxation delays
(VAPOR; Griffey and Flamig, 1990). PRESS was performed again
but without water suppression with the same parameter values
except collecting only eight averages from the same voxel.
Each spectrum was visually reviewed to ensure adequate
signal to noise ratio, as well as the absence of artifacts.
Spectra were analyzed using LCModel version 6.3–0I
(Provencher, 1993) using a basis set of 21 metabolites including
creatine (Cr) and glutamate (Glu). Model metabolites and
concentrations used in the basis set are fully detailed in
the LCModel manual (http://s-provencher.com/pages/lcm-
manual.shtml). Poorly fitted metabolite peaks (Cramer-Rao
minimum variance bounds of >20% as reported by LCModel)
were excluded from further analysis.
Behavioral Testing
In cohort II, 42 animals (20 males and 22 females) were treated
with either NAC or vehicle 130 min prior to the assessment
of open field locomotor activity. Animals were brought back to
their home-cage for 10–15 min, and then PPI was performed
155min post-treatment. Behavioral testing was carried out under
stringent environmental control of housing and husbandry as
well as the handling of the mice, balance and uniformity in
testing, the experimenter, test location and standardized test
procedures. Behavioral testing was conducted in the light phase
of the light/dark cycle. After each individual test, boli and urine
were removed from the test arena which was cleaned with 1%
Anistelr solution (high level surface disinfectant, Trisel Solution
Ltd, Cambridgeshire, UK) to remove any odors. Experimenters
were blind to experimental treatment group during the testing.
Open Field Locomotor Activity
Locomotor activity in a novel open field area was assessed as
a measure of anxiety as previously published (Grayton et al.,
2013). Animals were placed in a square 40 × 40 cm arena
under white light (8 lux) for 10 min and video recorded.
The central (20 × 20 cm) and peripheral outer (remaining)
areas of the arena were defined and movements in each zone
were tracked with Ethovision software version 3.1 (Noldus
Information Technologies bv, Wageningen, Netherlands). Time
spent in the central zone was used as measure of anxiety, and
distance travelled in the arena was used as measure of locomotor
activity.
Prepulse Inhibition of the Acoustic Startle
Response
PPI was assessed using a chamber for mice which recorded startle
response amplitude (San Diego Instruments, San Diego, CA,
USA), following a previously well-validated protocol (Vuillermot
et al., 2011; Labouesse et al., 2013). Animals were placed in
the Plexiglas enclosure and presented with a series of discrete
trials. Four different trial types were used, including pulse alone
trials, prepulse alone trials, prepulse-pulse trials and no-stimulus
trials (where no sound was played other than the constant
background noise). The pulse and prepulse stimuli consisted
of a sudden elevation of the broadband white noise from the
background level of 65 dBA with a rise time of 0.2–1 ms, for 40
and 20 ms respectively. Three pulse intensities (100, 110 and 120
dBA), and three prepulse intensities (71, 77 and 83 dBA—which
corresponded to 6, 12 and 18 dBA above the background noise
respectively) were used. The onset of the pulse was presented 100
ms after the onset of the prepulse, for all prepulse-pulse trials.
Animals were allowed to adapt to the enclosure for 2 min
before the beginning of the first trial. They were presented with
six pulse only trials (two trials of each intensity) for habituation,
which were not included in the analysis. The test phase consisted
of 10 blocks of 16 discrete trials. Each block included three
pulse alone trials (100, 110 and 120 dBA), three prepulse alone
FIGURE 1 | (A) Typical placement of a striatal voxel on T2-weighted pilot MR images of the mouse brain; (B) In vivo localized 1H-MR spectrum from a striatal voxel
and (C) LCModel analysis of a 1H MR spectrum.
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trials (71, 77 and 83 dBA), nine prepulse-pulse trials (all possible
prepulse-pulse combinations), and one no-stimulus trial. Within
each block, the 16 trials were presented in pseudorandom order
and separated by a variable interval of 10–20 s (average 15 s).
For each trial type, average reactivity was calculated over the
whole experiment, excluding the first six pulse alone trials. PPI
wasmeasured as the percent inhibition of startle response (%PPI)
in pulse only trials. For each animal, it was calculated as follows:
[(mean reactivity on pulse alone trials) − (mean reactivity on
prepulse-pulse trials)/(mean reactivity on pulse alone trials)] ∗
100; for each pulse intensity (100, 110 and 120 dBA), and each
prepulse intensity (71, 77 and 83 dBA).
STATISTICAL ANALYSIS
1H-MRS and open field data were analyzed using a general
linear model (IBM SPSS Statistics version 21) including
group and sex as between subject factors. The time post-
dose, tpost−dose was included as covariate in the analysis of
metabolite concentrations, and correlations between metabolite
concentrations and tpost−dose were explored using Pearson
correlation coefficients.
For PPI analysis, reactivity to pulse alone trials were analyzed
in a 3× 2× 2 repeatedmeasures ANOVA (pulse level× group×
sex). %PPI data were analyzed in 3× 3× 2× 2 repeated measure
ANOVA (prepulse level × pulse level × group × sex). Where
there was a significant interaction between sex and another factor
on %PPI, data were re-analyzed separately for each sex.
RESULTS
Localized 1H-MRS of the Brain
Creatine (Cr)
A representative 1H-MRS spectrum of the left striatum is shown
in Figures 1B,C. There was no main effect of treatment or sex
on creatine (from creatine and phosphocreatine; all F(1,26) <
0.3, all p > 0.6). All subsequent metabolite concentrations were
therefore calculated in reference to Cr to account for potential
inter-individual differences in voxel composition (Gussew et al.,
2012).
Glutamate (Glu)
Glu/Cr concentrations were significantly lower in the NAC
treated group, as indicated by a main effect of treatment (F(1,26) =
5.77, p = 0.02). There was also amain effect of tpost−dose onGlu/Cr
(F(1,26) = 10.2, p = 0.004). Furthermore Glu/Cr was negatively
correlated with tpost−dose in the NAC group (r = −0.657, p =
0.008), but not in the vehicle group (r = −0.417, p = 0.108);
as there was no main effect of sex on Glu/Cr, both sexes were
examined together for the correlation analysis. Please refer to
Figure 2.
Open Field Locomotor Activity
Distance Travelled
There were main effects of treatment (F(1,38) = 4.90, p = 0.033)
and sex (F(1,38) = 17.98, p < 0.001) on distance travelled in the
FIGURE 2 | Glutamate/Creatine was negatively correlated with time
post-dose in the N-acetylcysteine (NAC)-treated group (A) but not in
the saline group. Glutamate/Creatine levels were significantly lower in NAC
treated animals (B), ∗p < 0.05.
arena of the open field, and no sex× treatment interaction. NAC
treated mice travelled significantly less than their saline treated
counterparts. Overall females travelled less distance than males
(please refer to Figure 3A).
Time in Central Zone
As shown in Figure 3B, there was a main effect of treatment on
time spent in central zone (F(1,38) = 8.22, p = 0.007), but no main
effect of sex and no sex × treatment interaction. NAC treated
animals spent significantly less time in the central zone. This
treatment main effect remained significant when co-varying for
distance travelled (F(1,37) = 8.39, p = 0.006), which indicates that
the difference was not likely to be due to a change in locomotor
activity.
Prepulse Inhibition (PPI) of the Acoustic
Startle Response
Mean reactivity was higher at higher pulse intensity in pulse
alone trials, as indicated by a mains effect of pulse intensity
(F(1.8,67.7) = 689.4, p < 0.001). There was also a main effect of sex
on reactivity to pulse alone trials (F(1,38) = 66.23, p < 0.001), as
well as a pulse× sex interaction (F(1.8,67.7) = 41.4, p < 0.001).
There was no main effect of treatment or sex on %PPI.
The treatment × sex interaction approached significance (F(1,38)
= 3.11, p = 0.086), therefore the analysis was repeated in
each sex separately (please refer to Figure 3C). There was no
effect of treatment on %PPI in males. However NAC treated
females displayed a significant reduction in %PPI compared with
controls (F(1,20) = 5.29, p = 0.032). The disruption of PPI by NAC
emerged independently of specific pulse and prepulse intensities,
as shown by non-significant interactions of pulse and prepulse
with treatment.
DISCUSSION
This study provided proof-of-concept evidence that glutamate
levels and behavior can be altered acutely by extra-synaptic
mechanisms targeting glial cells. Activation of system xc− by
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FIGURE 3 | NAC treatment reduced locomotor activity (main effect of treatment, p = 0.033) (A) and increased anxiety (main effect of treatment,
p = 0.007) (B), in females more than males. In (C), percent prepulse inhibition (%PPI) is shown as a function of the three pulse levels (100, 110 or 120 dBA), and
the three prepulse levels (6, 12 or 18 dBA above background level of 65 dBA). %PPI was reduced by NAC treatment in females only (main effect of treatment,
p = 0.032).
NAC lowered glutamate concentrations in the striatum in a time-
dependent fashion. NAC-treated animals displayed reduced
locomotor activity in the open field as well as increased anxiety,
which was independent from general activity levels. NAC
treatment reduced the prepulse inhibition of startle response in
females exclusively.
The acute glutamatergic effects of NAC observed in this
study are consistent with, and extend previous findings. For
example previous studies showed that NAC reduces excitatory
currents in an mGluR2/3 dependent fashion (Moran et al.,
2005; Kupchik et al., 2012). One 1H-MRS study in a mouse
model of schizophrenia found that chronic NAC treatment
reduces cortical glutamate levels in developing animals (Das
Neves Duarte et al., 2012). Here, we show that one dose of
NAC is sufficient to lower striatal glutamate in a time-dependent
fashion; the lowest glutamate levels are evident 120 min post-
dose and continue to decrease for at least 60 min. We report
that a single dose of NAC also disrupts behavior from 120 min
post-administration. We interpret the behavioral differences as
likely due to a glutamate decrease, but acknowledge the evidence
is indirect. These findings may have translational importance as
they suggest that targeting glia can shift glutamate levels; and this
is relevant to neurodevelopmental disorders such as ASD and
schizophrenia, where glial abnormalities and E/I imbalance are
prominent features.
Our finding of reduced striatal glutamate is analogous to the
decrease of glutamate and its metabolite glutamine observed in
the striatum of adult males with ASD (Horder et al., 2013). Our
observations of greater anxiety and impaired sensorimotor gating
in NAC-treated animals also mimics impairments commonly
found in ASD and related neurodevelopmental disorders
(McAlonan et al., 2002; Perry et al., 2007; Braga et al., 2013; Joshi
et al., 2013; Matson and Cervantes, 2014). Thus, although our
design did not make it possible to assess glutamate levels and
behavior in the same animals, behavioral findings may well relate
to a change in glutamate concentrations.
For example, locomotor activity, anxiety and PPI at least
partly depend on glutamatergic transmission (Takeuchi et al.,
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2001; O′Neill et al., 2003; Wieronska and Pilc, 2013; Saitoh
et al., 2014). Here, we report that indirect mGluR2/3 agonism
via NAC causes lower activity. This is consistent with a role
for mGluR2/3 in the tonic inhibition of locomotion; and the
observation that mGluR2/3 antagonism increases locomotion
(O′Neill et al., 2003). However, mGluR2/3 agonism has been
reported to both increase (Imre et al., 2006; Satow et al.,
2008) and decrease (Imre et al., 2006; Grivas et al., 2013)
anxiety, depending on the dose. Similarly, acute administration
of mGluR2/3 agonists has been reported to have either no
effect (intra-peritoneal administration of LY379268; Hikichi
et al., 2010), or impair (intracerebral administration of L-
CCG-I; Grauer and Marquis, 1999), PPI. Thus, the mGluR2/3
response is likely to be complex and depend on the dose
and administration regime of compounds targeting these
receptors.
Although we show here that NAC administration mimics
lower striatal glutamate and causes behavioral abnormalities
similar to those found in ASD, paradoxically, NAC has shown
clinical benefits in small scale double blind trials in this
condition (Hardan et al., 2012; Ghanizadeh and Moghimi-
Sarani, 2013). However, the latter study examined NAC as an
adjunct alongside risperidone, and a recently completed Clinical
Trial of NAC in ASD did not find evidence of efficacy (K.
Gray, personal communication). There are a number of possible
explanations for these inconsistencies. First, the acute effects
of NAC may be quite distinct from the effects of repeated
administration in clinical settings. Arguably, the glutamate
system responds differently to chronic modulation compared
to acute challenge. Secondly, the developmental stage studied
may be critical, as glutamate levels in humans are known
to vary with age (Segovia et al., 2001; Kaiser et al., 2005).
The clinical trials of NAC in ASD were mostly completed
in children (Hardan et al., 2012; Ghanizadeh and Moghimi-
Sarani, 2013), while we used adult animals. Third, the effects
of NAC may be different in a ‘‘disordered’’ system. We used
standard in-bred laboratory mice in this study; it is possible
that the effects of NAC would be different in a mouse model
showing baseline E/I imbalance. Some support for this latter
suggestion comes from preliminary work in schizophrenia. NAC
has shown benefits in adults with schizophrenia (Zavodnick
and Ali, 2014), but a study in healthy volunteers found that
NAC pretreatment worsened auditory mismatch negativity
following ketamine administration (Gunduz-Bruce et al., 2012),
a paradigm thought to mimic psychosis. Finally, it is possible
that the clinical benefits of chronic administration of NAC
are in fact mediated by its antioxidant actions, rather than
its glutamatergic action (Dean et al., 2009; Rushworth and
Megson, 2013). Thus, we emphasize that our findings do not
speak to the therapeutic use of NAC in neurodevelopmental
disorders, for which there is no clear consensus. Rather, we
suggest that our finding shows that modulating glutamate and
behavior via glial mechanisms is possible, and suggests that glial
mechanisms may be a tractable target for drugs which aim to
modulate E/I.
We acknowledge some unexpected findings in this study.
We elected to study NAC in both female and male animals
and found sex-differences in the PPI response following NAC
administration. PPI is particularly sensitive to sex-differences in
both laboratory animals (Lehmann et al., 1999; Ralph et al., 2001;
Zhang et al., 2015) and individuals with neurodevelopmental
disorders (Kumari et al., 2004; Gogos et al., 2009). Moreover,
although there were no treatment× sex interactions in measures
of activity and anxiety, the effects of NAC on these measures was
numerically greater in females compared to males. It is therefore
possible that female mice are more sensitive to the behavioral
consequences of the change in glutamate, however larger sample
sizes would be needed to explore this in more detail. It
would also be valuable to determine whether there are any sex
differences in glial mechanisms. We echo the call for more
research into sex differences in neurodevelopmental disorders,
particularly as it becomes apparent that their prevalence in
females may be higher than thought previously (Brix et al.,
2015). We also acknowledge that an important limitation of
this study was that we did not measure glutamate levels and
assess behavior in the same animals. The current design was
chosen to avoid confounds related to putting the same animals
through several experimental procedures sequentially. Previous
work has shown that invasive behavioral testing could induce
changes in neural activity patterns (Xu et al., 2012), and brain
metabolite levels (Zhou et al., 2012). On the other hand,
the imaging procedure, which required 2 h of anaesthesia,
is a significant exposure and could impact upon subsequent
behavioral testing. Therefore we chose to use a naïve cohort of
mice animals for the behavioral and the imaging experiments.
Future research will aim to correlate E/I and behavioral measures
in the same animals, possibly using ex vivo methods. Finally,
the PRESS spectroscopy acquisition protocol we used did not
allow for estimation of GABA concentration. Glutamate and
GABA are constantly in flux and measuring the other side of
the E/I ratio would be useful to obtain a fuller picture in the
future.
In summary, this work confirms that glial mechanisms
regulate glutamate acutely and have functional consequences in
adult animals. Glial cells may therefore be a potential drug target
for the development of new therapies for neurodevelopmental
disorders even in the adult system.
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